Abstract
Primary cutaneous aspergillosis is a rare, life-threatening, infectious complication in premature infants that may result in fulminant sepsis and subsequent multi-organ failure. In the past decade, the incidence of primary aspergillosis has increased significantly, whereas the high morbidity and mortality of invasive aspergillosis remains unaltered. In vitro studies reveal that more and more Aspergillus species seem to be refractory to the classical treatment with fluconazole or amphotericin B. This case report presents two extremely low birth weight infants (ELBW) with primary cutaneous aspergillosis, which was refractory to amphotericin B. Both patients were successfully treated with systemic voriconazole, an extended-spectrum triazole antifungal, supported by topical care. This paper provides the clinical manifestation, diagnostics and pharmacotherapy of primary cutaneous aspergillosis, as well as pharmacokinetic aspects of voriconazole in ELBW infants.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Woodruff CA, Hebert AA . Neonatal primary cutaneous aspergillosis: case report and review of literature. Pediatr Dermatol 2002; 19: 439–444.
Groll AH, Jaeger G, Allendorf A, Herrmann G, Schloesser R, von Loewenich V . Invasive pulmonary aspergillosis in an critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis 1998; 27: 437–452.
Galimberti R, Kowalczuk A, Parra IH, Ramos MG, Flores V . Cutaneous aspergillosis: a report of six cases. Br J Dermatol 1998; 139: 522–526.
Herron MD, Vanderhooft SL, Byington C, King JD . Aspergillosis in a 24-week newborn: a case report. J Perinat 2003; 23: 256–259.
Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A . Safety and pharmacokinetics of oral voriconazol in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395–402.
Chandrasekar PH, Manavathu E . Voriconazole: a second-generation triazole. Drugs of Today 2001; 37 (2): 135–148.
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.
Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Gháhramani P et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240–248.
Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166–2167.
Pennick GJ, Clark M, Sutton DA, Rinaldi MG . Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother 2003; 47: 2348–2350.
Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D . Pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546–2553.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE . Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157–1167.
Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND . Safety of voriconazole and dose individualization. Clin Infect Dis 2003; 36: 1087–1088.
Acknowledgements
We thank an anonymous peer reviewer for constructive feedback on the initial manuscript. We also thank Michael Hanna, PhD, for his support in revision and proofreading of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Frankenbusch, K., Eifinger, F., Kribs, A. et al. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. J Perinatol 26, 511–514 (2006). https://doi.org/10.1038/sj.jp.7211532
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jp.7211532
This article is cited by
-
Extrem kleines Frühgeborenes mit großflächiger Hautläsion
Monatsschrift Kinderheilkunde (2023)
-
Simultaneous primary invasive cutaneous aspergillosis in two preterm twins: case report and review of the literature
BMC Infectious Diseases (2017)
-
Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy
Clinical Pharmacokinetics (2016)
-
Primäre kutane Aspergillose bei einem extrem unreifen Frühgeborenen
Der Hautarzt (2013)